Please assess the completion status of the following clinical trial:

Trial Title: Re-boosting of HIV-1 Infected Subjects With Vacc-4x

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed immunization regimen with Vacc-4x active and stopped ART (at Week 28) in the CT-BI Vacc-4x 2007/1 study. (No re-start of ART is required).~2. Documented pre-study CD4 cell count ≥400x106/L.~3. Documented pre-study viral load \< 300 000copies/mL.~4. Signed informed consent.~Exclusion Criteria:~1. Reported AIDS-defining illness within the previous year.~2. Malignant disease.~3. On chronic treatment with immune-suppressive therapy.~4. Unacceptable values of the hematologic and clinical chemistry parameters, as judged by the Investigator, including creatinine values \>1.5 x upper limit of normal (ULN), and AST, ALT and alkaline phosphatase (ALP) values \>2.5 x ULN.~5. Concurrent chronic active infection such as viral hepatitis B or C or tuberculosis.~6. Pregnant or breastfeeding women.~7. Women of childbearing potential not using reliable and adequate contraceptive methods (defined as: use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; practicing abstinence; sterile) during the 5 weeks re-boosting period including the DTH and for 2 weeks after the DTH test, or sexually active male subjects with partners of child bearing potential unwilling to practice effective contraception during the 5 weeks re-boosting period including the DTH and for 12 weeks after the DTH-test.~8. Current participation in other clinical therapeutic studies.~9. Incapability of compliance to treatment protocol, in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 63 Years
- Healthy Volunteers: f

Study Arms:
- Re-boosting with Vacc-4x (Type: EXPERIMENTAL): Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).